Navigation Links
JCI table of contents: April 25, 2011
Date:4/25/2011

EDITOR'S PICK: Pelvic organs given the slip by the protein fibulin-5

Pelvic organ prolapse (POP) is a disabling condition that affects almost 50% of women over the age of 50. It occurs when the muscles and ligaments supporting a woman's pelvic organs weaken such that the pelvic organs slip out of place, often protruding into the vagina. For many affected women, treatment involves surgery. Defining the molecular mechanisms underlying POP could provide targets for nonsurgical approaches to treating the condition. In this context, a team of researchers, led by Hiromi Yanagisawa, at the University of Texas Southwestern Medical Center, Dallas, has now identified a key role for the protein fibulin-5 in preventing the development of POP in mice.

The team found that fibulin-5 prevents the development of POP in mice in two ways. First, it facilitates the assembly of normal elastic fibers that help keep pelvic organs in place. Second, it inhibits the activity of MMP9, a protein that degrades the elastic fibers that help keep pelvic organs in place. As vaginal tissue samples from women with POP also showed increased levels of MMP-9, the authors suggest that therapies targeting elastic fiberdegrading proteins may help prevent, or even ameliorate, POP in women.

Gina Northington, at the University of Pennsylvania School of Medicine, Philadelphia, discusses in detail the importance of this study in an accompanying commentary.

TITLE: Extracellular matrix proteases contribute to progression of pelvic organ prolapse in mice and humans

AUTHOR CONTACT:
Hiromi Yanagisawa
University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Phone: 214.648.7723; Fax: 214.648.1488; E-mail: hiromi.yanagisawa@utsouthwestern.edu.

View this article at: http://www.jci.org/articles/view/45636?key=c7a74618d3a706d6e2a5

ACCOMPANYING COMMENTARY
TITLE: Fibulin-5: two for the price of one maintaining pelvic support

AUTHOR CONTACT:
Gina M. Northington
University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Phone: 215.662.6361; Fax: 215.662.7929; E-mail: gnorthington@obgyn.upenn.edu.

View this article at: http://www.jci.org/articles/view/57438?key=dab0f15181873ab2fbf9


INFECTIOUS DISEASE: Targeting tissue destruction in tuberculosis

Infection with the bacterium Mycobacterium tuberculosis can cause tuberculosis. In most people, however, the bacteria do not cause disease but are sequestered in the lung in walled off compartments known as granulomas. By studying both human samples and mice expressing the human form of the protein MMP-1, a team of researchers, led by Paul Elkington, at Imperial College London, United Kingdom, has now generated data indicating that MMP-1 drives lung tissue destruction in granulomas. The team therefore suggests that targeting MMP-1 might provide a way to limit the damage caused by infection with Mycobacterium tuberculosis. This and other data indicating that MMPs represent viable therapeutic targets to control Mycobacterium tuberculosis infections are discussed in an accompanying commentary by Padmini Salgame, at the University of Medicine and Dentistry of New Jersey, Newark.

TITLE: MMP-1 drives immunopathology in human tuberculosis and transgenic mice

AUTHOR CONTACT:
Paul Elkington
Imperial College London, London, United Kingdom.
Phone: +44.20.8383.2733; Fax: +44.20.8383.3394; E-mail: p.elkington@imperial.ac.uk.

View this article at: http://www.jci.org/articles/view/45666?key=e1fa320bcbef4924b014

ACCOMPANYING COMMENTARY
TITLE: MMPs in tuberculosis: granuloma creators and tissue destroyers

AUTHOR CONTACT:
Padmini Salgame
University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, New Jersey, USA.
Phone: 973.972.8647; Fax: 973.972.0713; E-mail: salgampa@umdnj.edu.

View this article at: http://www.jci.org/articles/view/57423?key=3b7d5c2835bb456b9eab


ONCOLOGY: On the origin of the tumor

It is, in general, very hard to cure a cancer once it has become clinically apparent. By identifying the cells from which a cancer arises researchers hope that it might be possible to detect cancerous lesions at much earlier stages and treat them more successfully. With this in mind, Andrzej Dlugosz and colleagues, at the University of Michigan Medical School, Ann Arbor, have now identified in mice the cells from which two forms of basal cell carcinoma arise.

Basal cell carcinomas are the most common human cancers. Although uncontrolled Hedgehog signaling drives almost all basal cell carcinomas, it is not clear why they differ in appearance and can be divided into different types. In this study, Dlugosz and colleagues used engineered mouse models of basal cell carcinoma to determine that superficial basal cell carcinomalike tumors arise from interfollicular epidermis and nodular basal cell carcinomalike tumors from hair follicle stem cells, thereby generating data that indicate that the cell of origin influences the type of basal cell carcinoma that develops.

In an accompanying commentary, Ervin Epstein Jr., at Children's Hospital of Oakland Research Institute, Oakland, discusses how these data fit with other recent studies on the origin of basal cell carcinomas and open doors for further investigation.

TITLE: Basal cell carcinomas in mice arise from hair follicle stem cells and multiple epithelial progenitor populations

AUTHOR CONTACT:
Andrzej A. Dlugosz
University of Michigan Medical School, Ann Arbor, Michigan, USA.
Phone: 734.647.9482; Fax: 734.763.4575; E-mail: dlugosza@umich.edu.

View this article at: http://www.jci.org/articles/view/46307?key=c7a533e6844cbea21cad

ACCOMPANYING COMMENTARY
TITLE: Mommy where do tumors come from?

AUTHOR CONTACT:
Ervin H. Epstein Jr.
Children's Hospital of Oakland Research Institute, Oakland, California, USA.
Phone: 510.502.6144; Fax: 510.597.7096; E-mail: eepstein@chori.org.

View this article at: http://www.jci.org/articles/view/57700?key=2017457f482f64dda68e


INFLAMMATION: New role for energy generators in controlling inflammation

The inflammatory response is initiated as a protective response but if the response is sustained or excessive it leads to tissue damage. A team of researchers, led by Jahar Bhattacharya, at Columbia University College of Physicians and Surgeons, New York, has now identified in mice a new molecular mechanism that curbs excessive inflammation. Specifically, the team found that mitochondria (the energy generating compartments of a cell) in cells lining blood vessels in the lungs are key regulators of inflammation. As highlighted by both the authors and, in an accompanying commentary, Laura A. Dada and Jacob I. Sznajder, these data provide potential new therapeutic targets for the treatment of the deleterious effects of the inflammatory response.

TITLE: Activation of TNFR1 ectodomain shedding by mitochondrial Ca2+ determines the severity of inflammation in mouse lung microvessels

AUTHOR CONTACT:
Jahar Bhattacharya
Columbia University College of Physicians and Surgeons, New York, New York, USA.
Phone: 212.305.7093; Fax: 212.305.6724; E-mail: jb39@columbia.edu.

View this article at: http://www.jci.org/articles/view/43839?key=40f61efa7caa39f0b9d9

ACCOMPANYING COMMENTARY
TITLE: Mitochondrial Ca2+ and ROS take center stage to orchestrate TNF-alphamediated inflammatory responses

AUTHOR CONTACT:
Jacob I. Sznajder
Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Phone: 312.908.7737; Fax: 312.908.4650; E-mail: j-sznajder@northwestern.edu.

View this article at: http://www.jci.org/articles/view/57748?key=e6d32124ce06b2bc0ee8


GASTROENTEROLOGY: Cellular connection between inflammatory bowel disease and colon cancers

Individuals with the inflammatory bowel disease ulcerative colitis are at high risk for developing colon cancer, but the mechanisms underlying this are not completely understood. A team of researchers, led by Stefan Fichtner-Feigl, at the University of Regensburg, Germany, has now identified a defined population of immune cells known as macrophages that facilitate the development of colon cancer in a mouse model of ulcerative colitis. These cells were marked by expression of F4/80, high levels of CD11b, and low levels of Gr1 and promoted tumor development, in part, via the production of the tumor-promoting factors IL-6 and TGF-beta-1. The authors plan to investigate whether individuals with ulcerative colitis also have increased numbers of these macrophages and whether their presence can be used to predict the development of colon cancer.

TITLE: Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11bhighGr1low macrophages

AUTHOR CONTACT:
Stefan Fichtner-Feigl
University of Regensburg, Regensburg, Germany.
Phone: 49.941.944.6868; Fax: 49.941.944.6802; E-mail: stefan.fichtner@klinik.uni-regensburg.de.

View this article at: http://www.jci.org/articles/view/42540?key=54177aab46c50c356361


'/>"/>

Contact: Karen Honey
press_releases@the-jci.org
734-546-5242
Journal of Clinical Investigation
Source:Eurekalert

Related medicine news :

1. JCI online early table of contents: April 18, 2011
2. Accountable care organizations have potential to curb costs and improve health care
3. JCI online early table of contents: April 11, 2011
4. Wiley hosts developmental psychology roundtable at SRCD
5. Implantable Device May Lower Tough-to-Treat Hypertension
6. JCI online early table of contents: April 1, 2011
7. Tetanus Still Diagnosed in U.S., Although Its Preventable
8. JCI online early table of contents: March 23, 2011
9. DSF Charitable Foundation gives $3.9M to CMUs Center or Nucleic Acids Science & Technology
10. Gardening linked to increased vegetable consumption in older adults
11. JCI online early table of contents: March 14, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... , ... April 24, 2017 , ... ... within the telehealth industry, announces the company’s VideoMedicine mobile platform has launched Quick ... Available 24 hours a day, Quick Care provides patients with the option to ...
(Date:4/24/2017)... ... 2017 , ... Rod Burkett, CEO of Gardant Management Solutions, was recently featured ... at the forefront of Gardant since it was founded in 1999. His drive and ... of more than 40 new senior living communities. With his leadership, Gardant has grown ...
(Date:4/24/2017)... ... April 24, 2017 , ... Donna Parker, L. Ac. reads ... not found any of them to be very practical. She wanted to write a ... make changes in their health. It prompted her in writing “ A Clear Path ...
(Date:4/24/2017)... ... 2017 , ... Miami Periodontist and Dental Implant ... Foundation’s 2017 Symposium on Tissue Regeneration and Implant Dentistry held in Miami Beach ... Symposium at the Fontainebleau Hotel located in Miami Beach, FL. This annual symposium ...
(Date:4/23/2017)... ... April 23, 2017 , ... "An event Horizon is a place where the ... my Art and Music. These are created as Metaphysical Transformations where music, which is ... culminate to the ultimate singularity.", -- Karen Salicath Jamali , Karen will also preview ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Vivify Health, the pioneer ... has been awarded a very significant patent for the ... to continual care via digital health.  This landmark patent ... property and further secures Vivify,s position as the leader ... 2009, was the first company to apply consumer mobile ...
(Date:4/20/2017)... April 20, 2017 Research and Markets has ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ... ... delivery technologies will rise from USD 20 Billion in 2015 to ... Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market ...
(Date:4/20/2017)... Research and Markets has announced the ... Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies ... ... was valued at US$ 7,167.6 Mn in 2015, and is ... a CAGR of 5.6% from 2016 to 2024. ...
Breaking Medicine Technology: